120 related articles for article (PubMed ID: 8292602)
1. Comparison of calcium-dependent conformational changes in the N-terminal SH2 domains of p85 and GAP defines distinct properties for SH2 domains.
Mahadevan D; Thanki N; McPhie P; Beeler JF; Yu JC; Wlodawer A; Heidaran MA
Biochemistry; 1994 Jan; 33(3):746-54. PubMed ID: 8292602
[TBL] [Abstract][Full Text] [Related]
2. A divalent metal ion binding site in the kinase insert domain of the alpha-platelet-derived growth factor receptor regulates its association with SH2 domains.
Mahadevan D; Thanki N; Aroca P; McPhie P; Yu JC; Beeler J; Santos E; Wlodawer A; Heidaran MA
Biochemistry; 1995 Feb; 34(7):2095-106. PubMed ID: 7857921
[TBL] [Abstract][Full Text] [Related]
3. In vivo binding properties of SH2 domains from GTPase-activating protein and phosphatidylinositol 3-kinase.
Cooper JA; Kashishian A
Mol Cell Biol; 1993 Mar; 13(3):1737-45. PubMed ID: 8382774
[TBL] [Abstract][Full Text] [Related]
4. Solution structure of the C-terminal SH2 domain of the p85 alpha regulatory subunit of phosphoinositide 3-kinase.
Siegal G; Davis B; Kristensen SM; Sankar A; Linacre J; Stein RC; Panayotou G; Waterfield MD; Driscoll PC
J Mol Biol; 1998 Feb; 276(2):461-78. PubMed ID: 9512716
[TBL] [Abstract][Full Text] [Related]
5. Functional interactions between isolated SH2 domains and insulin/Ras signaling pathways of Xenopus oocytes: opposite effects of the carboxy- and amino-terminal SH2 domains of p85 PI 3-kinase.
Aroca P; Mahadevan D; Santos E
Oncogene; 1996 Nov; 13(9):1839-46. PubMed ID: 8934529
[TBL] [Abstract][Full Text] [Related]
6. Cooperative self-assembly of SH2 domain fragments restores phosphopeptide binding.
Williams KP; Shoelson SE
Biochemistry; 1993 Oct; 32(42):11279-84. PubMed ID: 7692962
[TBL] [Abstract][Full Text] [Related]
7. Identification of residues in GTPase-activating protein Src homology 2 domains that control binding to tyrosine phosphorylated growth factor receptors and p62.
Marengere LE; Pawson T
J Biol Chem; 1992 Nov; 267(32):22779-86. PubMed ID: 1385407
[TBL] [Abstract][Full Text] [Related]
8. In vitro association of the phosphatidylinositol 3-kinase regulatory subunit (p85) with the human insulin receptor.
Ottinger EA; Hui TY; Man Z; Barany G; Bernlohr DA
Int J Pept Protein Res; 1995 Nov; 46(5):346-53. PubMed ID: 8567177
[TBL] [Abstract][Full Text] [Related]
9. Controlled overexpression of selected domains of the P85 subunit of phosphatidylinositol 3-kinase reverts v-Ha-Ras transformation.
Zhang QX; Davis ID; Baldwin GS
Biochim Biophys Acta; 1996 Jul; 1312(3):207-14. PubMed ID: 8703989
[TBL] [Abstract][Full Text] [Related]
10. The C-terminal SH2 domain of p85 accounts for the high affinity and specificity of the binding of phosphatidylinositol 3-kinase to phosphorylated platelet-derived growth factor beta receptor.
Klippel A; Escobedo JA; Fantl WJ; Williams LT
Mol Cell Biol; 1992 Apr; 12(4):1451-9. PubMed ID: 1312663
[TBL] [Abstract][Full Text] [Related]
11. Specific binding of Fyn and phosphatidylinositol 3-kinase to the B cell surface glycoprotein CD19 through their src homology 2 domains.
Chalupny NJ; Aruffo A; Esselstyn JM; Chan PY; Bajorath J; Blake J; Gilliland LK; Ledbetter JA; Tepper MA
Eur J Immunol; 1995 Oct; 25(10):2978-84. PubMed ID: 7589101
[TBL] [Abstract][Full Text] [Related]
12. Multiple SH2-mediated interactions in v-src-transformed cells.
Koch CA; Moran MF; Anderson D; Liu XQ; Mbamalu G; Pawson T
Mol Cell Biol; 1992 Mar; 12(3):1366-74. PubMed ID: 1545818
[TBL] [Abstract][Full Text] [Related]
13. Yeast two-hybrid in vivo association of the Src kinase Lyn with the proto-oncogene product Cbl but not with the p85 subunit of PI 3-kinase.
Dombrosky-Ferlan PM; Corey SJ
Oncogene; 1997 May; 14(17):2019-24. PubMed ID: 9160881
[TBL] [Abstract][Full Text] [Related]
14. Conformational analysis of cyclic hexapeptides designed as constrained ligands for the SH2 domain of the p85 subunit of phosphatidylinositol-3-OH kinase.
Barchi JJ; Nomizu M; Otaka A; Roller PP; Burke TR
Biopolymers; 1996 Feb; 38(2):191-208. PubMed ID: 8589253
[TBL] [Abstract][Full Text] [Related]
15. Measurement of the binding of tyrosyl phosphopeptides to SH2 domains: a reappraisal.
Ladbury JE; Lemmon MA; Zhou M; Green J; Botfield MC; Schlessinger J
Proc Natl Acad Sci U S A; 1995 Apr; 92(8):3199-203. PubMed ID: 7536927
[TBL] [Abstract][Full Text] [Related]
16. The smaller isoforms of ankyrin 3 bind to the p85 subunit of phosphatidylinositol 3'-kinase and enhance platelet-derived growth factor receptor down-regulation.
Ignatiuk A; Quickfall JP; Hawrysh AD; Chamberlain MD; Anderson DH
J Biol Chem; 2006 Mar; 281(9):5956-64. PubMed ID: 16377635
[TBL] [Abstract][Full Text] [Related]
17. Localization of the insulin-like growth factor I receptor binding sites for the SH2 domain proteins p85, Syp, and GTPase activating protein.
Seely BL; Reichart DR; Staubs PA; Jhun BH; Hsu D; Maegawa H; Milarski KL; Saltiel AR; Olefsky JM
J Biol Chem; 1995 Aug; 270(32):19151-7. PubMed ID: 7642582
[TBL] [Abstract][Full Text] [Related]
18. Interaction of the p85 subunit of PI 3-kinase and its N-terminal SH2 domain with a PDGF receptor phosphorylation site: structural features and analysis of conformational changes.
Panayotou G; Bax B; Gout I; Federwisch M; Wroblowski B; Dhand R; Fry MJ; Blundell TL; Wollmer A; Waterfield MD
EMBO J; 1992 Dec; 11(12):4261-72. PubMed ID: 1330535
[TBL] [Abstract][Full Text] [Related]
19. Alternative modes of binding of proteins with tandem SH2 domains.
O'Brien R; Rugman P; Renzoni D; Layton M; Handa R; Hilyard K; Waterfield MD; Driscoll PC; Ladbury JE
Protein Sci; 2000 Mar; 9(3):570-9. PubMed ID: 10752619
[TBL] [Abstract][Full Text] [Related]
20. Quantitative analysis of SH2 domain binding. Evidence for specificity and competition.
Wood ER; McDonald OB; Sahyoun N
J Biol Chem; 1992 Jul; 267(20):14138-44. PubMed ID: 1629214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
